The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease

NCT05995392 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Dry Eye Disease

Interventions

DRUG: Topical spironolactone ophthalmic solution, 0.005 mg/cc
DRUG: Placebo

Sponsor

Richard W Yee, MD